Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Convertible Debt: 2023-2024

Historic Convertible Debt for Mirum Pharmaceuticals (MIRM) over the last 2 years, with Dec 2024 value amounting to $308.1 million.

  • Mirum Pharmaceuticals' Convertible Debt rose 0.55% to $309.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $309.4 million, marking a year-over-year increase of 0.55%. This contributed to the annual value of $308.1 million for FY2024, which is 0.54% up from last year.
  • Mirum Pharmaceuticals' Convertible Debt amounted to $308.1 million in FY2024, which was up 0.54% from $306.4 million recorded in FY2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Convertible Debt peaked at $308.1 million during FY2024, and registered a low of $306.4 million during FY2023.
  • Its 2-year average for Convertible Debt is $307.3 million, with a median of $307.3 million in 2023.
  • Data for Mirum Pharmaceuticals' Convertible Debt shows a peak YoY increased of 0.54% (in 2024) over the last 5 years.
  • Mirum Pharmaceuticals' Convertible Debt (Yearly) stood at $306.4 million in 2023, then increased by 0.54% to $308.1 million in 2024.